ApoE production in human monocytes and its regulation by inflammatory cytokines

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Braesch Andersen, Sten ^a   Paulie, Staffan ^a   Smedman, Christian ^b   Mia, Sohel ^b   Kumagai Braesch, Makiko ^c  

^a Mabtech ^*  (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS, CD14; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; GENE EXPRESSION; GPI-LINKED PROTEINS; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MONOCYTES; PRIMARY CELL CULTURE; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893925215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079908     Document Type: Article

References (47)

1. Grainger DJ, Reckless J, McKilligin E (2004) Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 173: 6366-6375. (Pubitemid 39487796)
2. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, et al. (1995) Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96: 2170-2179.
3. Ali K, Middleton M, Pure E, Rader DJ (2005) Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 97: 922-927. (Pubitemid 41552678)
4. Zhou Y, Cheshire A, Howell LA, Ryan DH, Harris RB (1999) Neuroautoantibody immunoreactivity in relation to aging and stress in apolipoprotein Edeficient mice. Brain Res Bull 49: 173-179. (Pubitemid 29319267)
5. Utermann G (1975) Isolation and partial characterization of an arginine-rich apolipoprotein from human plasma very-low-density lipoproteins: apolipoprotein E. Hoppe Seylers Z Physiol Chem 356: 1113-1121.
6. Rall SC Jr, Weisgraber KH, Mahley RW (1982) Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 257: 4171-4178.
7. Zannis VI, vanderSpek J, Silverman D (1986) Intracellular modifications of human apolipoprotein E. J Biol Chem 261: 13415-13421.
8. Mahley RW, Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537.
9. Weisgraber KH, Mahley RW (1978) Apoprotein (E-A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem 253: 6281-6288. (Pubitemid 9023296)
10. Weisgraber KH, Shinto LH (1991) Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma. Impact on receptor binding activity. J Biol Chem 266: 12029-12034. (Pubitemid 21907052)
11. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630.
12. Fazio S, Babaev VR, Burleigh ME, Major AS, Hasty AH, et al. (2002) Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. J Lipid Res 43: 1602-1609. (Pubitemid 35168274)
13. Zhu Y, Bellosta S, Langer C, Bernini F, Pitas RE, et al. (1998) Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci U S A 95: 7585-7590. (Pubitemid 28293296)
14. Zanotti I, Pedrelli M, Poti F, Stomeo G, Gomaraschi M, et al. (2010) Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 31: 74-80.
15. Vitek MP, Brown CM, Colton CA (2009) APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30: 1350-1360.
16. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA (1994) Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 159: 124-139. (Pubitemid 24381044)
17. Avila EM, Holdsworth G, Sasaki N, Jackson RL, Harmony JA (1982) Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells. J Biol Chem 257: 5900-5909. (Pubitemid 12012052)
18. Roselaar SE, Daugherty A (1998) Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res 39: 1740-1743. (Pubitemid 28411160)
19. Zuckerman SH, Evans GF, O'Neal L (1992) Cytokine regulation of macrophage apo E secretion: opposing effects of GM-CSF and TGF-beta. Atherosclerosis 96: 203-214.
20. Werb Z, Chin JR (1983) Endotoxin suppresses expression of apoprotein E by mouse macrophages in vivo and in culture. A biochemical and genetic study. J Biol Chem 258: 10642-10648. (Pubitemid 14244325)
21. Hayashi C, Madrigal AG, Liu X, Ukai T, Goswami S, et al. (2010) Pathogen-mediated inflammatory atherosclerosis is mediated in part via Toll-like receptor 2-induced inflammatory responses. J Innate Immun 2: 334-343.
22. Werb Z, Chin JR, Takemura R, Oropeza RL, Bainton DF, et al. (1986) The cell and molecular biology of apolipoprotein E synthesis by macrophages. Ciba Found Symp 118: 155-171.
23. Brand K, Mackman N, Curtiss LK (1993) Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest 91: 2031-2039. (Pubitemid 23141475)
24. Duan H, Li Z, Mazzone T (1995) Tumor necrosis factor-alpha modulates monocyte/macrophage apoprotein E gene expression. J Clin Invest 96: 915-922.
25. Zuckerman SH, O'Neal L (1994) Endotoxin and GM-CSF-mediated downregulation of macrophage apo E secretion is inhibited by a TNF-specific monoclonal antibody. J Leukoc Biol 55: 743-748. (Pubitemid 24207404)
26. Aleong R, Blain JF, Poirier J (2008) Pro-inflammatory cytokines modulate glial apolipoprotein E secretion. Curr Alzheimer Res 5: 33-37. (Pubitemid 351536352)
27. Madan M, Bishayi B, Hoge M, Amar S (2008) Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. Atherosclerosis 197: 504-514. (Pubitemid 351417861)
28. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R (1999) Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19: 2364-2367. (Pubitemid 29477837)
29. Smedman C, Ernemar T, Gudmundsdotter L, Gille-Johnson P, Somell A, et al. (2011) FluoroSpot analysis of TLR-activated monocytes reveals several distinct cytokine secreting subpopulations. Scand J Immunol 75: 249-258.
30. Taleb S, Tedgui A, Mallat Z (2010) Adaptive T cell immune responses and atherogenesis. Curr Opin Pharmacol 10: 197-202.
31. Lahoute C, Herbin O, Mallat Z, Tedgui A (2011) Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 8: 348-358.
32. Hansson GK (1993) Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 69: S38-41.
33. Laskowitz DT, Lee DM, Schmechel D, Staats HF (2000) Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 41: 613-620. (Pubitemid 30220665)
34. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. (2010) Immunity 33: 375-386.
35. Wong KL, Tai JJ, Wong WC, Han H, Sem X, et al. (2011) Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118: e16-31.
36. Skrzeczynska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, et al. (2008) Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. Scand J Immunol 67: 152-159.
37. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226. (Pubitemid 41057736)
38. Wagner H (2004) The immunobiology of the TLR9 subfamily. Trends Immunol 25: 381-386.
39. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, et al. (2006) IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 440: 949-953.
40. Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25: 1776-1785.
41. Glund S, Krook A (2008) Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol (Oxf) 192: 37-48. (Pubitemid 350265360)
42. Febbraio MA, Pedersen BK (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16: 1335-1347. (Pubitemid 34913306)
43. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, et al. (2004) The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor? Proc Nutr Soc 63: 263-267. (Pubitemid 38787476)
44. Petersen AM, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98: 1154-1162. (Pubitemid 40396484)
45. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, et al. (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288: E155-162. (Pubitemid 40023802)
46. Fisman EZ, Tenenbaum A (2010) The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol 9: 62.
47. Song H, Saito K, Fujigaki S, Noma A, Ishiguro H, et al. (1998) IL-1 beta and TNF-alpha suppress apolipoprotein (apo) E secretion and apo A-I expression in HepG2 cells. Cytokine 10: 275-280. (Pubitemid 28227070)